Galectin Therapeutics Inc. — Form 10-Q Summary
Business Context and Reporting Period
Galectin Therapeutics Inc. is a development-stage biotechnology company developing galectin-targeting therapies for cancer and fibrotic disease. The filing covers the three and nine months ended September 30, 2012. The company had no commercial revenue and all proposed products remained in preclinical or clinical development.
- Lead programs: GM-CT-01 for cancer therapy and GR-MD-02 for liver fibrosis and NASH.
- Corporate actions: A one-for-six reverse stock split became effective in March 2012, followed by a NASDAQ Capital Market listing.
- Shares outstanding: 15.97 million as of November 9, 2012.
Financial Performance and Position
| Metric | Three Months Ended September 30 | Nine Months Ended September 30 |
|---|---|---|
| Research and development expense | $1.409 million in 2012; $0.655 million in 2011 | $3.525 million in 2012; $2.690 million in 2011 |
| General and administrative expense | $1.487 million in 2012; $1.378 million in 2011 | $3.992 million in 2012; $4.347 million in 2011 |
| Total operating expenses | $2.896 million in 2012; $2.033 million in 2011 | $7.517 million in 2012; $7.037 million in 2011 |
| Net loss | $2.689 million in 2012; $2.028 million in 2011 | $7.299 million in 2012; $7.547 million in 2011 |
| Net loss applicable to common stockholders | $2.985 million, or $0.19 per share | $8.173 million, or $0.55 per share |
| Net cash used in operating activities | Not provided for the quarter | $5.749 million in 2012; $4.134 million in 2011 |
- Cash and cash equivalents: $11.059 million at September 30, 2012, compared with $6.397 million at December 31, 2011.
- Total assets: $11.193 million; total liabilities were $1.442 million.
- Liquidity: Current assets were $11.148 million versus current liabilities of $1.442 million.
- Debt: The filing reports no outstanding convertible debt at September 30, 2012. The company had redeemable convertible preferred stock with recorded values totaling approximately $6.694 million and redemption values totaling approximately $10.267 million.
- Financing: The March 2012 common stock and warrant offering generated $12.0 million of gross proceeds and $10.403 million of net proceeds.
- Equity dilution: Common shares outstanding increased from 12.920 million at December 31, 2011 to 15.966 million at September 30, 2012. Outstanding warrants totaled 7.424 million and options totaled 3.542 million at September 30, 2012.
Material Changes Versus the Prior Comparable Period
- Research and development expense increased 115% in the third quarter and 31% for the first nine months, primarily because of increased preclinical work on GR-MD-02 and additional clinical-program manufacturing costs.
- General and administrative expense increased 8% in the third quarter but decreased 8% for the first nine months, reflecting lower legal and Colombia-related business-development costs, partly offset by higher stock-based compensation and public-company expenses.
- Net loss increased in the third quarter, but the nine-month net loss improved by $248,000 compared with 2011, largely because 2011 included a $515,000 expense primarily related to warrant-liability fair-value changes.
- The company recognized $200,000 of other income after terminating its agreement with PROCAPS because PROCAPS had not obtained required Colombian regulatory approval.
- Cash increased by $4.662 million during the first nine months, primarily because the $10.403 million equity offering proceeds exceeded operating cash usage.
- Effective October 1, 2012, the company relocated its headquarters from Massachusetts to Georgia and expected annual operating-lease savings of approximately $226,000.
Guidance, Outlook, Risks, and Unusual Items
- Management stated that available cash at September 30, 2012 was expected to fund operations through 2013. Additional financing will be required, and failure to raise capital or commercialize products before the end of 2013 could require the company to cease operations or seek bankruptcy protection.
- The company expected to complete the first stage of Cohort 1 in its GM-CT-01 Phase I/II melanoma trial in the second quarter of 2013. Stage 2 was estimated to require approximately $1.0 million of company funding if the trial met its response criteria.
- Management planned to file an FDA IND for GR-MD-02 by January 2013 and expected to begin a Phase I NASH study in early 2013. These milestones were subject to regulatory, clinical, financing, and operational uncertainties.
- The company terminated its PROCAPS agreement and stated that it had no current plans to continue seeking Colombian approval for GM-CT-01.
- A $1.0 million severance obligation to the former CEO remains accrued and is payable upon specified milestones, including certain regulatory, financing, market-capitalization, or bankruptcy events. An arbitration demand was denied on November 1, 2012, but a related Massachusetts Wage Act lawsuit against the CEO and CFO was pending; the company expected to indemnify them.
- The company continued to face substantial risks associated with clinical development, regulatory approval, intellectual-property protection, dependence on outside capital, limited operating history, competition, and potential stock-price volatility.
- Stock-based compensation expense was $2.170 million for the first nine months of 2012, with $6.125 million of unrecognized compensation related to unvested options expected to be recognized over approximately 3.7 years.
Most Important Facts for Investors to Verify
- Whether cash usage and financing access support operations beyond 2013.
- Progress, enrollment, safety, and efficacy results for the GM-CT-01 melanoma trial.
- Whether the GR-MD-02 IND was filed and whether clinical development began as planned.
- The potential dilution from 7.424 million warrants, 3.542 million options, and preferred-stock conversion rights.
- The status and ultimate cost of the pending Wage Act lawsuit and the accrued $1.0 million severance obligation.
- Whether any product has obtained regulatory approval or generated recurring commercial revenue; the filing reports none through September 30, 2012.